In November 2012, MorphoSys announced a collaboration with Lanthio Pharma, a Dutch biopharmaceutical company focused on discovering and developing lantipeptides. MorphoSys also made an equity investment in Lanthio Pharma as part of the company’s Series A financing round. Lantipeptides comprise a novel class of therapeutics with high target selectivity and improved drug-like properties. Lanthio Pharma's technology LanthioPep can be used to identify peptides which are selective for a specific disease target and to stabilize them in their optimal structural conformation for receptor binding.
In October 2014, MorphoSys exercised an option within the agreement and acquired Lanthio Pharma's lantipeptide technology for its proprietary drug discovery activities. By exercising the option, MorphoSys took over the lantipeptide technology and all related intellectual property.
In May 2015, MorphoSys acquired Lanthio Pharma. With the transaction, MorphoSys´s growing proprietary portfolio was complemented by promising lantipeptide drug candidates, including Lanthio Pharma´s lead candidate LP2 (now MOR107) which is being developed against diabetic nephropathie and fibrotic diseases.